Effect of corticosteroid on the antitumor activity of lymphokine-activated killer cells and interleukin 2 in mice

M. Z. Papa, J. T. Vetto, S. E. Ettinghausen, J. J. Mulé, S. A. Rosenberg

Research output: Contribution to journalArticle

Abstract

The adoptive transfer of lymphokine-activated killer (LAK) cells combined with low dose interleukin 2 (IL-2) mediates the regression of established pulmonary metastases in mice and has efficacy in the treatment of human cancer. Systemic administration of high dose IL-2 alone can mediate tumor regression. Cortisone acetate (CA), 25-75 mg/kg, was administered daily to mice receiving high dose IL-2 for 10 days. CA significantly reduced the toxicity induced by IL-2; 38 of 48 mice receiving CA survived compared to 0 of 30 controls (P <0.0001). In addition, CA administration caused a decrease in IL-2-induced 125I-labeled albumin leakage in mouse organs. However, CA abrogated the in vivo antitumor effect of high dose IL-2, and to a lesser extent the therapeutic effect of exogenous LAK cells plus lower dose IL-2. Mice treated with 100,000 units of IL-2 showed 98, 63, and 33% reductions of pulmonary metastases in Hanks' balanced salt solution, 25 mg Ca/kg, and 75 mg Ca/kg groups, respectively; treatment with LAK and 7,500 units of IL-2 resulted in reductions of 94, 77, and 57% in these same groups. CA treatment of animals did not affect LAK generation, although the absolute number of LAK precursors was greatly reduced. These results show that although CA can reduce the toxic effect(s) of IL-2, it can be detrimental to successful immunotherapy using this approach.

Original languageEnglish (US)
Pages (from-to)5618-5623
Number of pages6
JournalCancer Research
Volume46
Issue number11
StatePublished - 1986
Externally publishedYes

Fingerprint

Lymphokine-Activated Killer Cells
Interleukin-2
Adrenal Cortex Hormones
Lymphokines
Neoplasm Metastasis
Lung
Adoptive Transfer
Poisons
Therapeutic Uses
cortisone acetate
Interleukin-10
Immunotherapy
Albumins
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Papa, M. Z., Vetto, J. T., Ettinghausen, S. E., Mulé, J. J., & Rosenberg, S. A. (1986). Effect of corticosteroid on the antitumor activity of lymphokine-activated killer cells and interleukin 2 in mice. Cancer Research, 46(11), 5618-5623.

Effect of corticosteroid on the antitumor activity of lymphokine-activated killer cells and interleukin 2 in mice. / Papa, M. Z.; Vetto, J. T.; Ettinghausen, S. E.; Mulé, J. J.; Rosenberg, S. A.

In: Cancer Research, Vol. 46, No. 11, 1986, p. 5618-5623.

Research output: Contribution to journalArticle

Papa, MZ, Vetto, JT, Ettinghausen, SE, Mulé, JJ & Rosenberg, SA 1986, 'Effect of corticosteroid on the antitumor activity of lymphokine-activated killer cells and interleukin 2 in mice', Cancer Research, vol. 46, no. 11, pp. 5618-5623.
Papa MZ, Vetto JT, Ettinghausen SE, Mulé JJ, Rosenberg SA. Effect of corticosteroid on the antitumor activity of lymphokine-activated killer cells and interleukin 2 in mice. Cancer Research. 1986;46(11):5618-5623.
Papa, M. Z. ; Vetto, J. T. ; Ettinghausen, S. E. ; Mulé, J. J. ; Rosenberg, S. A. / Effect of corticosteroid on the antitumor activity of lymphokine-activated killer cells and interleukin 2 in mice. In: Cancer Research. 1986 ; Vol. 46, No. 11. pp. 5618-5623.
@article{fa00bfc83c57441e9dc3af2c1869c265,
title = "Effect of corticosteroid on the antitumor activity of lymphokine-activated killer cells and interleukin 2 in mice",
abstract = "The adoptive transfer of lymphokine-activated killer (LAK) cells combined with low dose interleukin 2 (IL-2) mediates the regression of established pulmonary metastases in mice and has efficacy in the treatment of human cancer. Systemic administration of high dose IL-2 alone can mediate tumor regression. Cortisone acetate (CA), 25-75 mg/kg, was administered daily to mice receiving high dose IL-2 for 10 days. CA significantly reduced the toxicity induced by IL-2; 38 of 48 mice receiving CA survived compared to 0 of 30 controls (P <0.0001). In addition, CA administration caused a decrease in IL-2-induced 125I-labeled albumin leakage in mouse organs. However, CA abrogated the in vivo antitumor effect of high dose IL-2, and to a lesser extent the therapeutic effect of exogenous LAK cells plus lower dose IL-2. Mice treated with 100,000 units of IL-2 showed 98, 63, and 33{\%} reductions of pulmonary metastases in Hanks' balanced salt solution, 25 mg Ca/kg, and 75 mg Ca/kg groups, respectively; treatment with LAK and 7,500 units of IL-2 resulted in reductions of 94, 77, and 57{\%} in these same groups. CA treatment of animals did not affect LAK generation, although the absolute number of LAK precursors was greatly reduced. These results show that although CA can reduce the toxic effect(s) of IL-2, it can be detrimental to successful immunotherapy using this approach.",
author = "Papa, {M. Z.} and Vetto, {J. T.} and Ettinghausen, {S. E.} and Mul{\'e}, {J. J.} and Rosenberg, {S. A.}",
year = "1986",
language = "English (US)",
volume = "46",
pages = "5618--5623",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Effect of corticosteroid on the antitumor activity of lymphokine-activated killer cells and interleukin 2 in mice

AU - Papa, M. Z.

AU - Vetto, J. T.

AU - Ettinghausen, S. E.

AU - Mulé, J. J.

AU - Rosenberg, S. A.

PY - 1986

Y1 - 1986

N2 - The adoptive transfer of lymphokine-activated killer (LAK) cells combined with low dose interleukin 2 (IL-2) mediates the regression of established pulmonary metastases in mice and has efficacy in the treatment of human cancer. Systemic administration of high dose IL-2 alone can mediate tumor regression. Cortisone acetate (CA), 25-75 mg/kg, was administered daily to mice receiving high dose IL-2 for 10 days. CA significantly reduced the toxicity induced by IL-2; 38 of 48 mice receiving CA survived compared to 0 of 30 controls (P <0.0001). In addition, CA administration caused a decrease in IL-2-induced 125I-labeled albumin leakage in mouse organs. However, CA abrogated the in vivo antitumor effect of high dose IL-2, and to a lesser extent the therapeutic effect of exogenous LAK cells plus lower dose IL-2. Mice treated with 100,000 units of IL-2 showed 98, 63, and 33% reductions of pulmonary metastases in Hanks' balanced salt solution, 25 mg Ca/kg, and 75 mg Ca/kg groups, respectively; treatment with LAK and 7,500 units of IL-2 resulted in reductions of 94, 77, and 57% in these same groups. CA treatment of animals did not affect LAK generation, although the absolute number of LAK precursors was greatly reduced. These results show that although CA can reduce the toxic effect(s) of IL-2, it can be detrimental to successful immunotherapy using this approach.

AB - The adoptive transfer of lymphokine-activated killer (LAK) cells combined with low dose interleukin 2 (IL-2) mediates the regression of established pulmonary metastases in mice and has efficacy in the treatment of human cancer. Systemic administration of high dose IL-2 alone can mediate tumor regression. Cortisone acetate (CA), 25-75 mg/kg, was administered daily to mice receiving high dose IL-2 for 10 days. CA significantly reduced the toxicity induced by IL-2; 38 of 48 mice receiving CA survived compared to 0 of 30 controls (P <0.0001). In addition, CA administration caused a decrease in IL-2-induced 125I-labeled albumin leakage in mouse organs. However, CA abrogated the in vivo antitumor effect of high dose IL-2, and to a lesser extent the therapeutic effect of exogenous LAK cells plus lower dose IL-2. Mice treated with 100,000 units of IL-2 showed 98, 63, and 33% reductions of pulmonary metastases in Hanks' balanced salt solution, 25 mg Ca/kg, and 75 mg Ca/kg groups, respectively; treatment with LAK and 7,500 units of IL-2 resulted in reductions of 94, 77, and 57% in these same groups. CA treatment of animals did not affect LAK generation, although the absolute number of LAK precursors was greatly reduced. These results show that although CA can reduce the toxic effect(s) of IL-2, it can be detrimental to successful immunotherapy using this approach.

UR - http://www.scopus.com/inward/record.url?scp=0023038364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023038364&partnerID=8YFLogxK

M3 - Article

C2 - 3489525

AN - SCOPUS:0023038364

VL - 46

SP - 5618

EP - 5623

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 11

ER -